IP Library Patent Application 13632919
Patent Application
App. No. 13/632,919

ANTIPARASITIC FORMULATIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/632,919
Abstract

Fipronil formulations and fipronil/S-methoprene co-formulations are provided herein. These formulations optionally contain one or more additional active ingredient(s). The formulations comprise an organic solvent, an alcohol co-solvent, and one or more antioxidants and without any crystallization inhibitor. The formulations provided herein are antiparasitic, and can be used, for example, to combat dog and cat parasites, such as, fleas and ticks.

Claims (34)

1 . A parasiticidal spot-on formulation comprising

fipronil or a veterinary acceptable salt thereof, which is present from about 9% to about 11% by weight of the formulation;

at least one C 1 -C 6 alcohol co-solvent, wherein the total amount of the at least one C 1 -C 6 alcohol co-solvent is up to about 5% by weight of the formulation;

one or more antioxidants, wherein the total amount of the one or more antioxidants is about 0.005% to about 1.0% by weight of the formulation;

at least one organic solvent which is one or more glycol ethers selected from the group consisting of diethylene glycol monoethyl ether, ethylene glycol monoethyl ether, dipropylene glycol n-butyl ether, dipropylene glycol monomethyl ether, and combinations thereof, wherein the total amount of the at least one organic solvent makes up the balance of the formulation; and

the formulation does not contain a surfactant or a crystallization inhibitor.

2 . The formulation of claim 1 , wherein fipronil or a veterinary acceptable salt thereof is present at about 9.8% w/w of the formulation.

3 . The formulation of claim 1 , wherein the at least one C 1 -C 6 alcohol co-solvent is selected from the group consisting of ethanol, propanol, isopropanol, and a combination thereof.

4 . The formulation of claim 1 , wherein the at least one C 1 -C 6 alcohol co-solvent is present from about 3% to about 5% w/w of the formulation.

5 . The formulation of claim 1 , wherein the at least one C 1 -C 6 alcohol co-solvent is present at about 5% w/w of the formulation.

6 . The formulation of claim 1 , wherein the at least one C 1 -C 6 alcohol co-solvent is ethanol, and is present at about 5% w/w of the formulation.

7 . The formulation of claim 1 , wherein the at least one C 1 -C 6 alcohol co-solvent is isopropanol, and is present at about 5% w/w of the formulation.

8 . The formulation of claim 1 , wherein the one or more antioxidants are selected from the group consists of butylated hydroxylanisole (BHA), butylated hydroxyltoluene (BHT), and α-Tocopherol.

9 . The formulation of claim 1 , wherein the one or more antioxidants are butylated hydroxylanisole (BHA) and butylated hydroxyltoluene (BHT).

10 . The formulation of claim 9 , wherein BHA is present at about 0.02% w/w and BHT is present at about 0.01% w/w of the formulation.

11 . The formulation of claim 1 , wherein the one or more antioxidants are butylated hydroxylanisole (BHA), butylated hydroxyltoluene (BHT), and α-Tocopherol.

12 . The formulation of claim 11 , wherein BHA is present at about 0.02% w/w, BHT is present at about 0.01% w/w, and α-Tocopherol is present at about 0.01% w/w of the formulation.

13 . The formulation of claim 1 , wherein the at least one organic solvent is diethylene glycol monoethyl ether.

14 . The formulation of claim 1 , wherein the at least one organic solvent is present from about 76% to about 90% w/w of the formulation.

15 . The formulation of claim 13 , wherein diethylene glycol monoethyl ether is present from about 76% to about 86% of the formulation.

16 . The formulation of claim 1 , further comprising S-methoprene, or a veterinary acceptable salt thereof.

17 . The formulation of claim 16 , wherein S-methoprene is present at about 8.8% w/w of the formulation.

18 . The formulation of claim 1 , which comprises

about 9.8% w/w of fipronil;

about 5% w/w of ethanol;

about 0.02% w/w of BHA;

about 0.01% w/w of BHT;

about 0.01% w/w of α-Tocopherol; and

balance diethylene glycol monoethyl ether.

19 . The formulation of claim 18 , which further comprises about 8.8% w/w of S-methoprene.

20 . The formulation of claim 16 , further comprising a knock-down agent.

21 . The formulation of claim 20 , wherein the knock-down agent is permethrin or a veterinary acceptable salt thereof.

22 . The formulation of claim 1 , further comprising pyriproxyfen or a veterinary acceptable salt thereof.

23 . The formulation of claim 22 , wherein the pyriproxyfen is present from about 3% to about 10% by weight of the formulation.

Assignments (4)
FIRST LIEN PATENT SECURITY AGREEMENT (TL) Recorded Oct 28, 2024
From: PETIQ, INC.; PETIQ, LLC; TRURX LLC; VELCERA, LLC; FIDOPHARM, INC.; SERGEANT’S PET CARE PRODUCTS, LLC
To: ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 069272/0659 →
ABL PATENT SECURITY AGREEMENT Recorded Oct 28, 2024
From: PETIQ, INC.; PETIQ, LLC; TRURX LLC; VELCERA, LLC; FIDOPHARM, INC.; SERGEANT’S PET CARE PRODUCTS, LLC
To: KEYBANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 069272/0670 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2013
From: PRESTON, JOHN
To: VELCERA, INC.
Reel/Frame 030515/0312 →
CHANGE OF NAME Recorded May 30, 2013
From: VELCERA, INC.
To: FIDOPHARM, INC.
Reel/Frame 030515/0362 →